Cancer drug delays not due to PBAC processes

"cancer" written in letterpress blocks
The Pharmaceutical Benefits Advisory Committee has spoken out against a perception that delays in access to the listing of cancer (and other) medicines are due to PBAC processes. PBAC informed the Senate Community Affairs References Committee Inquiry into the availability of new, innovative and specialist cancer drugs in Australia that in fact, delays are often

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous Consumers to pay more under deregulated pharmacy?
Next US pharmacists: more patient care, less dispensing